Combining dabrafenib and the MEK inhibitor trametinib or the BRAF inhibitor encorafinib with the MEK inhibitor binimetinib results in impressive and durable responses and also prolonged survival in patients with metastatic melanoma (12–14). This evidence concerns the gene MAP2K7 and metastatic melanoma.